跳至主要内容
临床试验/NL-OMON40725
NL-OMON40725已完成4 期

Pharmacokinetic Profile of Ropivacaïne after Periarticular Local Infiltration Analgesia for Primary Total Knee Arthroplasty - LIAkin

Sint Maartenskliniek0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - age 50-80 years
  • - ASA physical health classification I * II
  • - Body Mass Index (BMI) < 40
  • - patient planned for a primary unilateral posterior-stabilized tri-compartmental cemented total knee replacement (Genesis II - PS) under unilateral spinal anesthesia with 2 mL hyperbaric bupivacaine 0.5%
  • - scheduled for fast-track protocol TKA
  • - haemoglobin (Hb) concentration * 7.5 mMol/L
  • - written informed consent

排除标准

  • - Placement of a surgical drain
  • - Contra-indications for spinal anesthesia
  • - Known hypersensitivity to amide-type local anesthetics
  • - Hepatic or renal insufficiency
  • - Use of fluvoxamine, ciprofloxacin, ketoconazole, erythromycin, clarithromycin, itraconazole, or rifampicin because of their effect on ropivacaine clearance.
  • - Any other reason which in the opinion of the investigator makes the patient unsuitable for participation in the study

研究者

相似试验